Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3 K/Akt pathway. (January 2018)

• Record Type: Journal Article
• Authors: Yu, Xiaolan; Yang, Yingcheng; Li, Yan; Cao, Yong; Tang, Li; Chen, Feng; Xia, Jiyi
• Is Part Of: International journal of biochemistry & cell biology. Volume 94(2018)
• Page Start: 107
• Page End: 118
• Publication Date: 2018-01
• Subjects: lncRNAs long noncoding RNAs -- BDLNR baicalein down regulated long noncoding RNA -- FBS fetal bovine serum -- RACE rapid amplification of cDNA ends -- qRT-PCR quantitative real-time polymerase chain reaction -- EdU ethynyl deoxyuridine -- TUNEL TdT-mediated dUTP nick end labeling -- PCD programmed cell death -- RIP RNA immunoprecipitation -- ChIP chromatin immunoprecipitation; Baicalein -- Cervical cancer -- Progression -- Long noncoding RNA -- PI3 K/Akt pathway; Biochemistry -- Periodicals; Cytology -- Periodicals; Biochemistry -- Periodicals; Cell Biology -- Periodicals; Biochimie -- Périodiques; Cytologie -- Périodiques; Biochimie; Cytologie; Biochemistry; Cytology; Ressource Internet (Descripteur de forme); Périodique électronique (Descripteur de forme); Periodicals; 572.05
• DOI: 10.1016/j.biocel.2017.11.009
• Languages: English
• ISSNs: 1357-2725

Abstract

Highlights: Baicalein down-regulated BDLNR in a dose- and time-dependent manner in cervical cancer. BDLNR is required for the anti-cancer effects of baicalein in cervical cancer. BDLNR activates PIK3CA expression and PI3 K/Akt pathway via binding to YBX1. BDLNR is upregulated in cervical cancer and indicates poor prognosis of cervical cancer patients. Abstract: Baicalein, an active flavonoid extracted from the root of Scutellaria baicalensis Georgi, has fascinating anti-cancer effects on many cancers. Our previous study also found that baicalein inhibited cervical cancer cell proliferation and migration, and induced cervical cancer cell apoptosis and cell cycle arrest. However, the molecular mechanisms underlying the anti-cancer effects of baicalein are largely unknown. In this study, we identified a novel long noncoding RNA (lncRNA), which is downregulated by baicalein in a dose- and time-dependent manner in cervical cancer. We named this lncRNA as baicalein down-regulated long noncoding RNA (BDLNR). Gain-of- and loss-of-function assays showed that BDLNR was required for baicalein-induced cell proliferation inhibition, cell death induction, migration inhibition, and in vivo tumor growth inhibition of cervical cancer. Mechanistically, BDLNR physically bound to YBX1, recruited YBX1 to PIK3CA promoter, activated PIK3CA expression and PI3 K/Akt pathway. Furthermore, BDLNR was upregulated in cervical cancer and associated with poor prognosis of cervical cancer patients. Collectively, our data demonstrated that BDLNR mediated the anti-cancer effects of baicalein in cervical cancer via activating PI3 K/Akt pathway, and implied that BDLNR would be potential therapeutic target for enhancing the anti-cancer effects of baicalein in cervical cancer.